Cargando…
Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
BACKGROUND: Surgery remains the frontline therapy for patients with localized clear cell renal cell carcinoma (ccRCC); however, 20%–40% recur. Angiogenesis inhibitors have improved survival in metastatic patients and may result in responses in the neoadjuvant setting. The impact of these agents on t...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710285/ https://www.ncbi.nlm.nih.gov/pubmed/33208553 http://dx.doi.org/10.1172/jci.insight.132852 |